Innoviva (INVA) vs Korsana Biosciences (KRSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Korsana Biosciences (KRSA) has outperformed Innoviva (INVA) over the past year, gaining 90.0% versus a gain of 22.4%. Over five years, INVA leads with a +26.8% price change compared with -91.1% for KRSA. Korsana Biosciences is the larger company by market cap ($1.53 billion vs $1.51 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INVA | KRSA |
|---|---|---|
| Share price | $20.87 | $33.51 |
| Market cap | $1.51B | $1.53B |
| 1-day change | -0.90% | +6.37% |
| YTD return | +5.35% | +276.94% |
| 1-year return | +22.44% | +89.97% |
| 5-year return | +26.79% | -91.10% |
| P/E ratio (TTM) | 4.88 | — |
| Forward P/E | 9.44 | — |
| EPS (TTM) | $4.28 | $-7.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.15 | $59.36 |
| 52-week low | $16.52 | $7.19 |
| Distance from 52-week high | -17.02% | -43.55% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +67.70% | +31.30% |
| Average volume | 819.96K | 29.26K |
| Shares outstanding | 72.25M | 45.54M |
| Employees | 159 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRSA has outperformed INVA by 67.5 percentage points over the past year.
About Innoviva
INVA stock →Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 159 employees
About Korsana Biosciences
KRSA stock →Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
INVA vs KRSA FAQ
Which is bigger, Innoviva or Korsana Biosciences?
Korsana Biosciences (KRSA) is larger, with a market capitalization of $1.53B compared with $1.51B for Innoviva (INVA).
Which stock has performed better over the past year, INVA or KRSA?
KRSA returned +89.97% over the past 12 months, compared with +22.44% for INVA (price return, excluding dividends). Past performance does not predict future results.
Are Innoviva and Korsana Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.